Company intelligence / Profile preview
Agna Biopharmaceutical
Guangdong Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Agna Biopharmaceutical has developed mRNA vaccines for COVID‑19, including delta/omicron variants. Its lead program RBMRNA‑176 is in Phase 2 clinical trials for COVID‑19, with other mRNA vaccine candidates also advancing through early-stage clinical development. The company possesses proprietary RNAi and LNP delivery platforms. No detailed efficacy or safety results are publicly summarized as of the latest update.
- Therapeutic areas
- Infectious Diseases
- Modalities
- mRNA-based drugsRNA therapyVaccineLipid nanoparticle delivery therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Guangzhou Ribobio Co., Ltd.Guangzhou Medical University
Beyond the preview
Go deeper on Agna Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agna Biopharmaceutical.